ERAS Stock Analysis: Buy, Sell, or Hold?
ERAS - Erasca, Inc. Common Stock
$18.47
0.55 (3.07%)
▲
5d:
+23.55%
30d:
+37.02%
90d:
+11.27%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Smart Money Distribution
None View Scanner →
Strength: 7.7/10
Get Alerted When ERAS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: ERAS is 13.7% above its trading range ($16.25). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: ERAS is 13.7% above its trading range ($16.25). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: ERAS is currently trading at $18.47, which is considered extended relative to its 30-day fair value range of $12.42 to $16.25.
Technical Outlook: Technically, ERAS is showing sideways momentum. The price is approaching resistance at $18.46. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: ERAS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $21.00 (+13.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ERAS is showing sideways momentum. The price is approaching resistance at $18.46. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: ERAS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $21.00 (+13.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$12.42 -
$16.25
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.3%
Protect Your Profits
ERAS is technically overbought (RSI 72). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price significantly overextended (+13.7% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.1%)
- BULLISH: Trading below Wall St target ($21.00)
Trading Range Analysis
30-Day Trading Range
$12.42 -
$16.25
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$13.60
Resistance Level
$18.46
Current Trend
Sideways
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-32.14
Wall Street Target
$21.00
(+13.7%)
Share & Embed Analysis
Last updated: July 02, 2026 10:34 PM ET
Data refreshes hourly during market hours. Next update: 11:34 PM
Data refreshes hourly during market hours. Next update: 11:34 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ERAS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Ebun Garner
SELL
80000 shares
2026-04-01
Shannon Morris
SELL
20000 shares
2026-03-04
Ebun Garner
SELL
120000 shares
2026-01-07
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 55 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 63 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 63 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
Advanced ERAS Option Strategies
Professional options setups generated by AI based on today's ERAS price and gamma walls.
